Cholera is a diarrheal disease that continues to burden vulnerable populations globally, primarily due to lack of clean water, optimal sanitation and adequate health infrastructure. Understanding the kinetics of antibody responses elicited by toxigenic infection can inform the Sero-epidemiological estimation of disease burden and impact of vaccination efforts. While antibody kinetics have been well-described in South Asia, such studies based in Africa are lacking, despite the ongoing prevalence of cholera in that region. We enrolled stool culture-positive cholera patients admitted to cholera treatment centers in Goma, Democratic Republic of Congo (DRC) between August 2020 and October 2023. Blood samples were collected upon enrollment and during follow-up home visits. We performed vibriocidal assays against O1 Inaba and Ogawa on 212 serum samples from 116 patients, 101 of whom had serotype information available (53% Male; 62% Female, Median age 8 (IQR 4-18). Vibriocidal antibody responses peaked between day 7 and 40 post symptom onset and then waned, with nearly all samples declining to a titer of 320 or lower by day 90, and 160 or lower by day 180. We used a Bayesian exponential decay model to show that there is an approximately 88% probability of a slower decay in participants over 5 years of age compared to younger aged subjects. Our findings corroborate the findings of prior studies conducted in hyperendemic areas in South Asia and provide critical data to inform the timing of vaccination campaigns and interpretation of serosurveillance results in African populations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888488 | PMC |
http://dx.doi.org/10.1101/2025.02.26.25322966 | DOI Listing |
Front Immunol
March 2025
Rheumatology Unit, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged as an effective treatment for RA. This narrative review provides an update on TCZ's efficacy and safety based on data from randomized controlled trials (RCTs) and real-world evidence (RWE).
View Article and Find Full Text PDFImmunohorizons
February 2025
Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Whether epigenetic factor UTX, a histone H3 lysine 27 (H3K27) demethylase, is critical for type 2 immunity, including allergic sensitization and antigen-driven anaphylaxis, is unclear. We used UTXfl/fl x Lck-Cre mice with UTX-deficient T cells (UTX-TCD) to determine whether T cell-specific UTX expression regulates antigen-specific IgE production after airway sensitization to peanut and anaphylaxis following intraperitoneal (i.p.
View Article and Find Full Text PDFJ Korean Med Sci
March 2025
Emerging Infectious Diseases Research Institute, Chungnam National University Hospital, Daejeon, Korea.
Background: We evaluated severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)-specific humoral and cellular responses for up to 6 months after the 3rd dose of ancestral coronavirus disease 2019 (COVID-19) vaccination in people living with HIV (PLWH) and healthy controls (HCs) who were not infected with COVID-19.
Methods: Anti-spike receptor-binding domain IgG (anti-RBD IgG) concentrations using chemiluminescence immunoassay and neutralizing antibodies using focus reduction neutralization test (FRNT) were assessed at 1 week after each dose of vaccination, and 3 and 6 months after the 3rd dose in 62 PLWH and 25 HCs. T-cell responses using intracellular cytokine stain were evaluated at 1 week before, and 1 week and 6 months after the 3rd dose.
Proc Natl Acad Sci U S A
March 2025
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS), which is linked to Epstein-Barr virus (EBV) infection, preceding the disease. The molecular mechanisms underlying this connection are only partially understood. We previously described molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and three human CNS proteins: anoctamin-2 (ANO2), alpha-B crystallin (CRYAB), and glial cellular adhesion molecule (GlialCAM).
View Article and Find Full Text PDFPediatr Infect Dis J
March 2025
National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Background: A birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters.
Methods: Children from our previous randomized controlled trial who received a monovalent 3-component aP and hepatitis B vaccine at birth (aP group) or hepatitis B only (control group) followed by Infanrix hexa at 2, 4 and 6 months of age were randomized to receive either high or low-dose diphtheria-tetanus acellular pertussis combination vaccine (DTPa-Infanrix/dTpa-Boostrix) at 18 months and 4 years of age.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!